MEXICO CITY, Dec. 10 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), a leading Mexican over-the-counter ("OTC") pharmaceuticals and personal care products company, announced today its 2009 earnings guidance. The Company expects to reach organic growth without considering acquisitions in the range of 21% - 22% in net sales and an EBITDA(I) margin in the range of 27% - 28%. These estimates are based on the organic growth of core products (products launched during and before 2007); the full year effect in sales of those products launched during 2008; the growth of Genomma Lab's international operations; as well as the Company's launch program of product line extensions and new brands in new categories and in those in which the Company already participates.
Genomma Lab expects to maintain its strategy of brand acquisitions and, on a timely basis, will inform the market on any completed transaction, as well as the corresponding change to the Company's earnings guidance. As of the close of the third quarter 2008, the Company had a cash balance and equivalents of Ps. 1,073 million that may be used partially or totally for potential brand acquisitions.
Genomma Lab will continue its efforts to increase its share in the Mexican personal care and over-the-counter markets. The value of such markets is approximately Ps. 75 billion(II) and Ps. 19 billion(III), respectively.
Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.
Genomma Lab performed its Initial Public Offering in June 2008, through a combined offering (mainly primary) and is listed on the Mexican Stock Exchange under the ticker symbol "LAB" (Bloomberg: labb.mx).
Web Site: www.genommalab.com (I) EBITDA is defined as Operating Income plus Depreciation and Amortization (II) Source: Euromonitor (2006) (III) Source: Datamonitor (2007) Investor Relations in Mexico City: Tel: +52 (55) 5081 0000 Ext. 4250 E-mail: firstname.lastname@example.org In New York: i-advize Corporate Communications, Inc. Tel: (212) 406-3692 E-mail: email@example.com
|SOURCE Genomma Lab Internacional, S.A.B. de C.V.|
Copyright©2008 PR Newswire.
All rights reserved